Inhibition of Antiestrogen-Promoted Pro-Survival Autophagy and Tamoxifen Resistance in Breast Cancer through Vitamin D Receptor

Round 1

Reviewer 1 Report

This manuscript presents an original study about an interesting subject.

I have just few comments:

-“For 116 each GSE dataset, survival analysis was performed on patients with high (>median) versus low (<median) VDR expression.”

Could you specify if median value is included in >median or <median?

-“We also analyzed RFS in GSE-1456, a dataset of 159 cases of which only 39% were ER+ 235 and treated with TAM [38]. No association between VDR expression and RFS was seen.”
could you specify the P-value?

-"We determined whether VDR levels are predictive of relapse-free survival"  

It is better to define VDR levels as prognostic factors and not predictive factors and use the terminology: 'VDR levels are associated with RFS'

-"Recurrence or relapse-free survival (RFS) in human datasets was defined as 110 the interval from breast surgery to the diagnosis of the first local or distant recurrence"

what about last follow-up for subjects with no relapse? what about deaths? they should be mentioned. please specify how they are considered.

-Please indicate percentages of missing values and median follow-up.

Author Response

Please see attachment

Author Response File: Author Response.docx

Reviewer 2 Report

Thank you for your contributions.

This is well written and designed study to evaluate VitD supplementation o ER+ Breast cancer to

prevent recurrence. This study results provide the importance of vitaminD  supplementation to the

breast cancer patient survivors.  However, I wonder proper VitD dose or serum level of 25OHD in breast cancer patients according to your study results. Please add if possible.

Author Response

Please see the attachment

Author Response File: Author Response.docx